294
Participants
Start Date
May 11, 2020
Primary Completion Date
March 17, 2022
Study Completion Date
September 27, 2022
LY03003(Rotigotine,extended-release microspheres)
During the intervention, the initial dose was 14mg, and then was incremented in weekly units, 14mg each time, until the maximum dose of 56mg set in this study was reached 4 weeks after titration, the optimal therapeutic dose or the maximum tolerated dose was entered into the dosing maintenance period. After entering the maintenance period, no dose adjustment was performed, and the stable dose was maintained for 24 weeks
Placebo,extended-release microspheres
During the intervention,the initial does was 14mg,and then was incremented in weekly units,14mg each time,until the maximum does of 56mg set in this study was reached 4 weeks after titration,the optimal therapeutic does or the maximum tolerated does was entered into the dosing maintenance period.After entering the maintenance period,no does adjustment was performed,and the stable does was maintained for 24 weeks.
Xuanwu Hospital Capital Medical University, Beijing
Collaborators (1)
Parexel
INDUSTRY
Luye Pharma Group Ltd.
INDUSTRY